Clinical trials: Mucocutaneous Lymph Node Syndrome
Kawasaki Disease, Coronary Aneurysm
Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease
Kawasaki disease (KD) affects infants and young children causing inflammation of the skin and blood vessels including the coronary arteries of the heart.
- Trial name
- NCT01917721
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Hawaii Pacific Health
Kawasaki Disease
Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease
Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the developed world. Despite available treatment, 25% of children in San Diego County appropriately treated for KD develop coronary artery…
- Trial name
- NCT04747847
- Testing
- Atorvastatin and anakinra
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Diego
Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease
The purpose of this study is to evaluate the efficacy and safety of TA-650 in comparison with a control drug Polyethylene Glycol-treated Human Immunoglobulin (VGIH) in patients with Kawasaki disease refractory to initial therapy…
- Trial name
- NCT01596335
- Testing
- TA-650, Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
- Where
- 8 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Tanabe Pharma Corporation
Kawasaki Disease
Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease
Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the developed world. Despite available treatment, 25% of children in San Diego County appropriately treated for KD develop coronary artery…
- Trial name
- NCT02179853
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, San Diego
Mucocutaneous Lymph Node Syndrome, Kawasaki Disease
A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease
The purpose of this study is to determine whether Etanercept (Enbrel) when used in conjunction with IVIG and aspirin, improves treatment response to IVIG in patients with Kawasaki Disease. Funding Source- FDA/OOPD
- Trial name
- NCT00841789
- Testing
- Etanercept
- Where
- 8 sites in United States, Canada
- Volunteers
- 205 people
- Sponsor
- Michael Portman
Mucocutaneous Lymph Node Syndrome
KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)
Kawasaki disease (KD) is a self-limited illness that affects the heart blood vessels (coronary arteries) of infants and children and is now the most common cause of acquired heart disease in children.
- Trial name
- KIDCARE (NCT03065244)
- Testing
- IVIG, Infliximab
- Where
- 29 sites in United States
- Volunteers
- 105 people
- Sponsor
- University of California, San Diego
Kawasaki Disease
Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities
Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the developed world. Despite available treatment, 25% of children in San Diego County appropriately treated for KD develop coronary artery…
- Trial name
- NCT01431105
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, San Diego
Kawasaki Disease
A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease
Determine the predictive value of CARDIOLITE® rest and stress myocardial perfusion imaging (MPI) to define a pediatric population with Kawasaki Disease (KD) at high and low risk of developing cardiac events.
- Trial name
- NCT00162032
- Testing
- Sestamibi
- Where
- 50 sites in United States, Brazil and 5 more
- Volunteers
- 445 people
- Sponsor
- Lantheus Medical Imaging
Kawasaki Disease
Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease
The purpose of this study is to determine whether the addition of infliximab to standard primary therapy of intravenous immunoglobulin (IVIG) and high dose aspirin will reduce resistance to therapy in acute Kawasaki disease (KD).
- Trial name
- NCT00760435
- Testing
- Infliximab
- Where
- 2 sites in United States
- Volunteers
- 196 people
- Sponsor
- University of California, San Diego
Kawasaki Disease
Infliximab (Remicade) for Patients With Acute Kawasaki Disease
This study evaluates the safety of infliximab in infants and children with acute Kawasaki Disease.
- Trial name
- NCT00271570
- Testing
- Infliximab (Remicade), Intravenous immunoglobulin (IVIG)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Diego